Inhibition of matrix metalloproteinase activity prevents increases in myocardial tumor necrosis factor-alpha.
TNF-alpha is known to cause adverse myocardial remodeling. While we have previously shown a role for cardiac mast cells in mediating increases in myocardial TNF-alpha, however, matrix metalloproteinase (MMP) activation of TNF-alpha may also be contributory. We sought to determine the relative roles of MMPs and cardiac mast cells in the activation of TNF-alpha in the hearts of rats subjected to chronic volume overload. Interventions with the broad spectrum MMP inhibitor, GM6001, or the mast cell stabilizer, nedocromil, were performed in the rat aortocaval fistula (ACF) model of volume overload. Myocardial TNF-alpha levels were significantly increased in the ACF. This increase was prevented by MMP inhibition with GM6001 (p< or =0.001 vs. ACF). Conversely, myocardial TNF-alpha levels were increased in the ACF+nedocromil treated fistula groups (p< or =0.001 vs. sham). The degradation of interstitial collagen volume fraction seen in the untreated ACF group was prevented in both the GM6001 and nedocromil treated hearts. Significant increases in LV myocardial ET-1 levels also occurred in the ACF group at 3days post-fistula. Whereas administration of GM6001 significantly attenuated this increase, mast cell stabilization with nedocromil markedly exacerbated the increase, producing ET-1 levels 6.5 fold and 2 fold greater than that in the sham-operated control and ACF group, respectively. The efficacy of the MMP inhibitor, GM6001, to prevent increased levels of myocardial TNF-alpha is indicative of MMP-mediated cleavage of latent extracellular membrane-bound TNF-alpha protein as the primary source of bioactive TNF-alpha in the myocardium of the volume overload heart.
Murray
David B
DB
Department of Pharmacology, University of Mississippi School of Pharmacy, University, MS 38677, USA. dmurray@olemiss.edu
Levick
Scott P
SP
Brower
Gregory L
GL
Janicki
Joseph S
JS
D000818:Animals; D002452:Cell Count; D015550:Cell Degranulation; D016207:Cytokines / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D008297:Male; D008407:Mast Cells / Q000166:cytology / Q000502:physiology; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism; D009206:Myocardium / Q000201:enzymology*; D018377:Neurotransmitter Agents / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D016207:Cytokines; D061965:Matrix Metalloproteinase Inhibitors; D018377:Neurotransmitter Agents; D014409:Tumor Necrosis Factor-alpha; D020782:Matrix Metalloproteinases
Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1251-7
18178727
Nature. 1997 Feb 20;385(6618):729-33
9034190
Nature. 1997 Feb 20;385(6618):733-6
9034191
Am J Physiol Heart Circ Physiol. 2002 Jun;282(6):H2152-8
12003823
Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H109-16
19429817
Eur J Immunol. 2004 Jul;34(7):1910-9
15214039
Anal Biochem. 2007 Jul 15;366(2):144-8
17548045
J Leukoc Biol. 2002 May;71(5):829-36
11994508
Basic Res Cardiol. 2008 Sep;103(5):485-92
18651091
Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):268-73
11834527
Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1462-8
19666842
Eur J Heart Fail. 2008 Feb;10(2):125-8
18234554
J Mol Cell Cardiol. 2010 Jul;49(1):70-8
20045005
Circ Res. 2002 Apr 19;90(7):807-13
11964374
Circulation. 1998 Aug 18;98(7):699-710
9715863
Am J Physiol Heart Circ Physiol. 2001 Mar;280(3):H984-91
11179039
J Clin Invest. 1995 Aug;96(2):1042-52
7635940
Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1216-22
17434981
Pharmacol Rep. 2008 Jul-Aug;60(4):524-31
18799821
J Med Chem. 1998 Jan 15;41(2):199-223
9457244
Circ Res. 2007 Jan 5;100(1):140-6
17170366
Am J Physiol. 1998 Mar;274(3):R577-95
9530222
Toxicology. 2006 Feb 15;219(1-3):142-9
16406210
Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H875-83
18065523
Basic Res Cardiol. 2007 Jan;102(1):63-72
16817025
Nature. 2004 Nov 25;432(7016):512-6
15543132
Basic Res Cardiol. 2010 Mar;105(2):301-13
19629561
Cardiovasc Res. 2003 Dec 1;60(3):608-16
14659806
Biochemistry. 2004 Jun 15;43(23):7227-35
15182168
Histochem J. 1999 Apr;31(4):221-9
10447063
Circulation. 2004 Jan 20;109(2):262-8
14699008
Basic Res Cardiol. 2010 Jan;105(1):139-50
19823892
J Leukoc Biol. 1995 May;57(5):774-7
7759957
Scand J Gastroenterol. 2006 Nov;41(11):1320-9
17060126
J Mol Cell Cardiol. 2002 Jan;34(1):51-62
11812164
Eur J Biochem. 1997 Dec 15;250(3):751-7
9461298
Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2295-9
15231495
Circulation. 1998 Apr 14;97(14):1382-91
9577950
Inflamm Res. 2008 May;57(5):241-6
18465084
J Mol Cell Cardiol. 2007 Jan;42(1):133-41
17101148
J Mol Cell Cardiol. 2008 Jul;45(1):56-61
18538342
J Card Fail. 2005 Sep;11(7):548-56
16198252
Am J Physiol Cell Physiol. 2007 Oct;293(4):C1362-73
17670887
Basic Res Cardiol. 2010 Mar;105(2):219-26
19859778
Circ Res. 1999 Nov 12;85(10):906-11
10559137
Am J Physiol Heart Circ Physiol. 2002 Aug;283(2):H518-25
12124196
Basic Res Cardiol. 2008 Sep;103(5):493-500
18600363
Exp Cell Res. 2004 Oct 1;299(2):465-75
15350544
Am J Physiol Heart Circ Physiol. 2000 Aug;279(2):H601-9
10924059
Circulation. 2001 Feb 27;103(8):1044-7
11222463